Objective: Using network pharmacology to predict the main active ingredients, targets and signaling pathways of Xuebijing injection in the treatment of hepatic ischemia-reperfusion injury and explore its potential mechanism of action. Methods: Screen the active ingredients and their targets of Danshen, Honghua, Chishao, Chuanxiong, and Danggui in Xuebijing injection through Traditional Chinese Medicine Systems Pharmacology (TCMSP) database and the Hepatic ischemia-reperfusion injury related targets through Online Mendelian Inheritance in Man (OMIM) and GeneCards Suite (The Human Gene Database) database. And acquire drug-disease intersection targets at the same time.The STRING database was used to construct a protein-protein interaction (PPI) network and topologically screen the central targets. Use the R language online search Bioconductor platform to perform GO function enrichment on the target; Database for Annotation, Visualization and Integrated Discovery (DAVID) database was used to perform KEGG channel enrichment analysis on the target. Use Cytoscape 3.7.2 to construct a “ ingredient-target-pathway ” network diagram and perform a topology analysis. Results: A total of 115 active ingredients were selected from Xuebijing injection, including Quercetin, Luteolin, Kaempferol, Beta-carotene, and Tanshinone Ⅱa ,etc. It corresponds to 217 targets. There are 1057 disease-related targets, and 114 drug-disease common targets. PPI topologically screened out 17 target proteins. Topological analysis of the network graph obtained 15 target genes. Thire intersection contains key targets such as JUN, PPARG, PTGS2, AKT1 and MAPK1. A total of 137 related signaling pathways were obtained by GO enrichment analysis. A total of 8 signaling pathways were obtained through KEGG enrichment (P <0.05, FDR <0.05), among which signaling pathways such as Toll-like receptors, T cell receptors, NOD-like receptors, VEGF, and ErbB played an important role in immune regulation, anti-apoptosis, anti-inflammatory, anti-oxidation, and promoting angiogenesis in the treatment. Conclusion: Xuebijing injection can treat hepatic ischemia-reperfusion injury through multiple components, multiple targets and multiple pathways.